‘Scromiting’ is the brutal new side effect of chronic cannabis use as ER visits surge

Cannabis hyperemesis syndrome (CHS) — a severe vomiting disorder linked to chronic cannabis use — is driving a surge in emergency-department presentations, with adolescent ED visits in the U.S. rising more than tenfold from 2016 to 2023. A George Washington University survey of 1,052 CHS patients found 44% had used cannabis regularly for over five years; episodes recur multiple times per year, standard anti-nausea drugs often fail, and treatment shortages force use of second- and third-line options, producing repeated costly ED visits. WHO added an official CHS diagnostic code on Oct. 1 and the CDC has adopted it, which should improve surveillance and identification of repeat cases.

Analysis

Market structure: Rapid recognition of cannabis hyperemesis syndrome (CHS) creates a regulatory and reputational headwind for high‑THC producers and retail MSOs (Curaleaf, Green Thumb, Tilray, Canopy) while creating modest revenue upside for ER/urgent care operators and addiction treatment providers. Expect consumer demand elasticity at the margin: if states or retailers add warnings, potency caps or age restrictions, sales of high‑THC SKUs could fall 5–15% in affected cohorts within 6–12 months, compressing margins for vertically integrated MSOs that rely on premium flower margins.

Risk assessment: Tail risks include rapid policy moves (state THC potency caps or advertising restrictions) or claimant class actions against major cannabis brands — both low probability but high impact, potentially wiping 20–40% off targeted MSO market caps. Near term (days–weeks) volatility should spike on legislative headlines; medium term (3–12 months) is driven by ICD coding uptake and insurance/ER claim flows; long term (1–3 years) depends on empirical data showing prevalence that could prompt federal/state regulation.

Trade implications: Relative value favors healthcare services and addiction/behavioral health providers over consumer cannabis exposure. Short bias on high‑THC focused MSOs and broad cannabis ETFs (MJ) vs long small positions in ER/urgent care operators (HCA, UHS) and specialty behavioral health (ACHC) looks attractive, with options to express asymmetric downside exposure on cannabis names while buying calls or call spreads on select healthcare names.

Contrarian angles: Consensus focuses on headline risk to cannabis demand, but underappreciated is potential product substitution (low‑THC, balanced CBD products, edibles) which could preserve market value for nimble producers; MSOs with diversified product mix or strong retail franchises may be insulated. The overreaction risk: indiscriminate shorting of large diversified names (Canopy, Tilray) could be premature if they pivot SKUs; monitor SKU mix shifts before scaling shorts.

Key Decisions for Investors

• Establish a tactical short (2–3% portfolio notional) via buying 3–6 month ATM puts on the MJ ETF (NYSEARCA: MJ) to hedge consumer cannabis demand risk; increase to 5% if a major state proposes THC potency caps or mandatory warning labels within 90 days.
• Open a 1–2% long position in Acadia Healthcare (NASDAQ: ACHC), target 12–18 month hold; buy a 6–12 month 1/2 width call spread if volatility >35% to cap cost, expecting 15–25% upside from incremental referrals and coding-driven reimbursements.
• Enter a pair trade: long 2% HCA Healthcare (NYSE: HCA) vs short 2% Curaleaf (OTC: CURLF) or Green Thumb (OTC: GTBIF) depending on liquidity; adjust sizes if state legislative action occurs — widen short to 4% if two or more states introduce THC restrictions within 6 months.
• Buy selective 9–12 month 25–35% OTM puts on high‑THC names (TLRY, CGC) sized 0.5–1% each to capture asymmetric downside from regulatory shocks; allocate total options exposure to no more than 3% of portfolio to limit gamma risk.
• Monitor next 30–90 days for these catalysts: (1) state legislature bills on THC limits, (2) CDC/FDA guidance or Medicaid coding changes for CHS, (3) major class‑action filings. If any catalyst triggers, reprice shorts to reach 4–6% notional within 10 trading days.